Mental Health Clinics in Baldwin, WI Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Heartfelt Therapy, Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1020 10th Ave Ste 117, Baldwin, WI 54002 Phone: 715-303-4370 Fax: 715-309-5133 |
Cobblestone Counseling, Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1820 4th Ave Apt 1, Baldwin, WI 54002 Phone: 715-928-1091 |
Boorman Counseling Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 550 10th Ave, Baldwin, WI 54002 Phone: 715-977-2441 |
News Archive
LevPharm to distribute Innovotech's bioFILM PA- test in Israel
Innovotech Inc., a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA- test to hospitals and clinics within Israel.
Research!America profiles various U.S. states regarding global health R&D
This post in the Global Health Technologies Coalition's (GHTC) "Breakthroughs" blog is the first of a series in which Research!America, a member of the GHTC, will profile various U.S. states based on an analyses the organization conducted "to measure the economic impact of [research & development (R&D)], highlighting the benefits of it for states across the nation," and to examine "what the [U.S.] is doing to advance global health R&D and why our continued support of such work is crucial for the health and prosperity of our future."
NIH awards grant to UND study that focuses on early formation of cancer-causing viruses
The list is long. From the common cold and influenza to HIV and measles, and from Zika to some cancers, all are caused by viruses — tiny packages of either DNA or RNA that wear a protein coat.
Researchers discover potential target for cancer-fighting drugs
As tumors grow, their centers are squeezed of oxygen. And so tumors must flip specific genetic switches to survive in these hypoxic environments.
Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 8 days ago